For the first time in an oral presentation at the 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Helsinki, Finland. Kris presented the positive top-line results that the Company had previously announced in November 2008. Difficile diarrhea, including treatment of infection by the hyper virulent NAP1/ribotype 027 outbreak strain..

/cgi-bin/prnh/20090413/LA97352LOGO) Dr. The trial met its primary endpoint with fidaxomicin achieving clinical cure compared to Vancocin(R). Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland SAN DIEGO, / - / -- Optimer Pharmaceuticals, Inc. In addition, patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006). OPTR) announced that the results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator Donall J.

"This study sho that fidaxomicin is as effective as vancomycin for treatment of C.